Regen BioPharma, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David Raymond Koos
- Full Time Employees
- 1
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 8697 La Mesa Boulevard La Mesa CA United States of America 91942
- IPO Date
- Oct 6, 2014
- CIK
- 0001589150
- Website
- regenbiopharmainc.com
- Similar Companies
- Business
- Regen BioPharma, Inc. is a biotechnology company focused on developing innovative regenerative medical therapies primarily targeting blood disorders, cancer, and autoimmune conditions. The company’s core products include HemaXellerate, a stem cell-derived cellular therapy using autologous stromal vascular fraction from adipose tissue designed to stimulate bone marrow regeneration, primarily for aplastic anemia and chemotherapy-induced bone marrow suppression; dCellVax and tCellVax, autologous dendritic cell- and T cell-based immunotherapies utilizing gene silencing technologies targeting immune checkpoints; small molecule drugs and RNA/DNA therapeutics including patented molecular targeting platforms like KimerApt and BORIS for cancer stem cell modulation and cellular immunotherapy; and DiffronC, a small molecule drug for blood disorders. Regen BioPharma develops its pipeline technologies with a combination of cell therapies, RNA vaccines, gene silencing, and molecular aptamer-based therapeutics. The company operates primarily in the United States and focuses on markets including hematology, oncology, and immunotherapy. Founded in 2008 and headquartered in San Diego, California, Regen BioPharma has progressed significantly with its lead candidate HemaXellerate, having received FDA clearance to initiate Phase I clinical trials to treat aplastic anemia and plans to seek Orphan Drug Designation for this therapy. The company actively works with contract research organizations to execute its clinical programs. Recent strategic developments include the expansion of HemaXellerate’s application beyond aplastic anemia to address chemotherapy-induced bone marrow suppression, targeting a market with substantial growth potential exceeding $1 billion annually. Regen BioPharma holds 11 issued patents with 17 additional patents pending across its platforms. Its recent corporate focus emphasizes advancing regenerative and immuno-oncology therapies through clinical validation and regulatory engagements. This includes ongoing responses to FDA feedback related to its orphan drug application submissions and plans to extend its technology platforms for broader hematological and oncological indications. The company's biotechnology portfolio and pipeline reflect a comprehensive approach combining autologous cell-derived treatments, gene silencing, and small molecule drugs aimed at transformative patient outcomes. Regen BioPharma's business model integrates research and development of novel therapies with a strategic focus on orphan and niche indications, leveraging its proprietary cell therapy and molecular targeting technologies to position itself in the growing regenerative medicine and biotech sectors. The company’s targeted customer base includes healthcare providers, research institutions, and pharmaceutical companies involved in cancer, autoimmune diseases, and rare blood disorders. Regen BioPharma remains publicly traded on the OTC Pink market under the ticker symbols RGBP and RGBPP. Overall, Regen BioPharma represents a specialized biotech firm developing next-generation cellular immunotherapies, RNA/DNA-based vaccines, and small molecule drugs with recent FDA clearance for clinical trials and a strategic focus on orphan drug designation and market expansion for its core regenerative medicine products. Its current pipeline and patent-protected technologies underscore its commitment to advancing innovative treatments for cancer, blood diseases, and immune-related conditions.
Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream
Goldman Small Cap Research Publishes New Research Report on Regen BioPharma, Inc.
Goldman Small Cap Research Publishes New Research Report on Regen BioPharma, Inc.
Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate™
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on September 25, 2024, At 4 pm Eastern Time
Regen BioPharma, Inc. to Discuss Plans to Move Forward with HemaXellerate into Clinical Phase 1 at the Emerging Growth Conference on April 4, 2024
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on January 10, 2024
Regen BioPharma, Inc. CEO Outlines Future Steps in CAR T Program
Regen BioPharma, Inc. to Discuss Confirmation Study Results on Its DuraCar Program at the Emerging Growth Conference on November 1, 2023
Regen BioPharma, Inc. Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program
Goldman Small Cap Research Publishes New Research Report on Regen BioPharma, Inc.
Studies On Regen BioPharma, Inc.'s DURACAR Indicate Potential Suppression Of Autoimmunity, Company Retains Contract Research Organization To Conduct Additional Confirmatory Studies
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 8, 2023
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on January 25, 2023
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on November 30, 2022